PCSK9 inhibition beyond monoclonal antibodies

PCSK9 Forum is pleased to announce that the next in this series of educational slide decks will be available soon. These focus on a different approach to inhibition of PCSK9, beyond monoclonal antibodies. Inclisiran is a novel, synthetic, small interfering RNA molecule which inhibits PCSK9 synthesis in hepatocytes. Thus, the effects of inclisiran are specific to intracellular PCSK9 production in the liver. Inclisiran is being investigated in the ORION clinical trial program. Different therapeutic approaches to PCSK9 inhibition - comparing monoclonal antibodies targeting PCSK9 with a small interfering RNA (siRNA) approach, the mechanism of inclisiran. Discussing the ORION clinical development program with inclisiran. Results from Phase II/III trials support a ‘one size fits all’ dosing regimen in at-risk patient groups, with a favourable safety profile.

These latest slide decks capture the essentials of the mechanism of inclisiran, and results from trials with this new therapeutic approach to inhibiting PCSK9. Accompanying videos provide expert interpretation for clinicians involved in the management of very high-risk patients with hypercholesterolaemia in their routine practice. These decks will provide a novel addition to the educational tools available for this new class of anti-PCSK9 therapeutic.

These unique educational resources will be launching shortly bookmark this page